{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:04Z","timestamp":1789628524337,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mallinckrodt Pharmaceuticals, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10620-026-10169-4","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:36:06Z","timestamp":1786469766000},"page":"5880-5889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Albumin in the Management of Hepatorenal Syndrome\u2013Acute Kidney Injury: Is There Ever Too Much?"],"prefix":"10.1007","volume":"71","author":[{"given":"Nicodemus","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-8869","authenticated-orcid":false,"given":"Florence","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"10169_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","volume":"69","author":"M Bernardi","year":"2020","unstructured":"Bernardi M, Angeli P, Claria J et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020;69:1127\u20131138. https:\/\/doi.org\/10.1136\/gutjnl-2019-318843.","journal-title":"Gut"},{"key":"10169_CR2","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1002\/hep.31836","volume":"74","author":"RK Jagdish","year":"2021","unstructured":"Jagdish RK, Maras JS, Sarin SK. Albumin in advanced liver diseases: The good and bad of a drug! Hepatology 2021;74:2848\u20132862. https:\/\/doi.org\/10.1002\/hep.31836.","journal-title":"Hepatology"},{"key":"10169_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.26338","volume":"58","author":"R Garcia-Martinez","year":"2013","unstructured":"Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013;58:1836\u20131846. https:\/\/doi.org\/10.1002\/hep.26338.","journal-title":"Hepatology"},{"key":"10169_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"European Association for the Study of the Liver","year":"2010","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397\u2013417. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.004.","journal-title":"J Hepatol"},{"key":"10169_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1014\u20131048. https:\/\/doi.org\/10.1002\/hep.31884.","journal-title":"Hepatology"},{"key":"10169_CR6","first-page":"122","volume":"17","author":"J Bannard-Smith","year":"2015","unstructured":"Bannard-Smith J, Alexander P, Glassford N et al. Haemodynamic and biochemical responses to fluid bolus therapy with human albumin solution, 4% versus 20%, in critically ill adults. Crit Care Resusc 2015;17:122\u2013128.","journal-title":"Crit Care Resusc"},{"key":"10169_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa2008290","volume":"384","author":"F Wong","year":"2021","unstructured":"Wong F, Pappas SC, Curry MP et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021;384:818\u2013828. https:\/\/doi.org\/10.1056\/NEJMoa2008290.","journal-title":"N Engl J Med"},{"key":"10169_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/apt.17195","volume":"56","author":"F Wong","year":"2022","unstructured":"Wong F, Pappas SC, Reddy KR et al. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther 2022;56:1284\u20131293. https:\/\/doi.org\/10.1111\/apt.17195.","journal-title":"Aliment Pharmacol Ther"},{"key":"10169_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2022166","volume":"384","author":"L China","year":"2021","unstructured":"China L, Freemantle N, Forrest E, ATTIRE Trial Investigators et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021;384:808\u2013817. https:\/\/doi.org\/10.1056\/NEJMoa2022166.","journal-title":"N Engl J Med"},{"key":"10169_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/HEP.0000000000000521","volume":"81","author":"J Trebicka","year":"2025","unstructured":"Trebicka J, Garcia-Tsao G. (2025) Controversies regarding albumin therapy in cirrhosis. Hepatology 2025;81:288\u2013303. https:\/\/doi.org\/10.1097\/HEP.0000000000000521.","journal-title":"Hepatology"},{"key":"10169_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMe2034425","volume":"384","author":"G Garcia-Tsao","year":"2021","unstructured":"Garcia-Tsao G. Terlipressin and intravenous albumin in advanced cirrhosis - Friend and foe. N Engl J Med 2021;384:869\u2013871. https:\/\/doi.org\/10.1056\/NEJMe2034425.","journal-title":"N Engl J Med"},{"key":"10169_CR12","unstructured":"European Medicine Agency. (2022) New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome. https:\/\/www.ema.europa.eu\/en\/news\/new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome."},{"key":"10169_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12876-015-0389-9","volume":"15","author":"F Salerno","year":"2015","unstructured":"Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol 2015;15:167. https:\/\/doi.org\/10.1186\/s12876-015-0389-9.","journal-title":"BMC Gastroenterol"},{"key":"10169_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, International Club of Ascites et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531\u2013537. https:\/\/doi.org\/10.1136\/gutjnl-2014-308874.","journal-title":"Gut"},{"key":"10169_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2016.10.024","volume":"66","author":"F Wong","year":"2017","unstructured":"Wong F, Angeli P. New diagnostic criteria and management of acute kidney injury. J Hepatol 2017;66:860\u2013861. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.024.","journal-title":"J Hepatol"},{"key":"10169_CR16","doi-asserted-by":"publisher","first-page":"1437.e1","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau R, Jalan R, Gines P et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1437.e1\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.042.","journal-title":"Gastroenterology"},{"key":"10169_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cgh.2023.04.034","volume":"21","author":"D Adebayo","year":"2023","unstructured":"Adebayo D, Wong F. Pathophysiology of hepatorenal syndrome - acute kidney Injury. Clin Gastroenterol Hepatol 2023;21:S1\u2013S10. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.034.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10169_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/hep.31798","volume":"74","author":"M Baldessare","year":"2021","unstructured":"Baldessare M, Naldi M, Zaccherini G et al. Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications. Hepatology 2021;74:2058\u20132073. https:\/\/doi.org\/10.1002\/hep.31798.","journal-title":"Hepatology"},{"key":"10169_CR19","doi-asserted-by":"publisher","first-page":"1467752","DOI":"10.3389\/fphar.2024.1467752","volume":"15","author":"MQ Li","year":"2024","unstructured":"Li MQ, Ge YD, Wang JJ et al. Impact of albumin infusion on prognosis in ICU patients with cirrhosis and AKI: insights from the MIMIC-IV database. Front Pharmacol 2024;15:1467752. https:\/\/doi.org\/10.3389\/fphar.2024.1467752.","journal-title":"Front Pharmacol"},{"key":"10169_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/gut.2006.107789","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310\u20131318. https:\/\/doi.org\/10.1136\/gut.2006.107789.","journal-title":"Gut"},{"key":"10169_CR21","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/liv.15367","volume":"42","author":"AS Allegretti","year":"2022","unstructured":"Allegretti AS, Subramanian RM, Francoz C, Olson JC, C\u00e1rdenas A. Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance. Liver Int 2022;42:2124\u20132130. https:\/\/doi.org\/10.1111\/liv.15367.","journal-title":"Liver Int"},{"key":"10169_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0003319711411704","volume":"63","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis GN, Pappas K, Tsianos EV. Differential effects of terlipressin on pulmonary and systemic hemodynamics in patients with cirrhosis and pulmonary hypertension: an echo study. Angiology 2012;63:199\u2013205. https:\/\/doi.org\/10.1177\/0003319711411704.","journal-title":"Angiology"},{"key":"10169_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/ejcts\/ezw410","volume":"51","author":"A Hussain","year":"2017","unstructured":"Hussain A, Bennett R, Haqzad Y et al. The differential effects of systemic vasoconstrictors on human pulmonary artery tension. Eur J Cardiothorac Surg 2017;51:880\u2013886. https:\/\/doi.org\/10.1093\/ejcts\/ezw410.","journal-title":"Eur J Cardiothorac Surg"},{"key":"10169_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.14309\/ajg.0000000000002574","volume":"119","author":"JS Bajaj","year":"2024","unstructured":"Bajaj JS, Kamath PS, Reddy KR et al. Predictors of respiratory failure development in a multicenter cohort of inpatients with cirrhosis. Am J Gastroenterol 2024;119:712\u2013718. https:\/\/doi.org\/10.14309\/ajg.0000000000002574.","journal-title":"Am J Gastroenterol"},{"key":"10169_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2022.03.043","volume":"77","author":"R Maiwall","year":"2022","unstructured":"Maiwall R, Kumar A, Pasupuleti SSR et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol 2022;77:670\u2013682. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.043.","journal-title":"J Hepatol"},{"key":"10169_CR26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jhep.2014.11.017","volume":"62","author":"T Th\u00e9venot","year":"2015","unstructured":"Th\u00e9venot T, Bureau C, Oberti F et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015;62:822\u2013830. https:\/\/doi.org\/10.1016\/j.jhep.2014.11.017.","journal-title":"J Hepatol"},{"key":"10169_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.JAA.0000000000000236","volume":"38","author":"T Ragaisis","year":"2025","unstructured":"Ragaisis T, Galush T, Breunig M. Using point-of-care ultrasound to assess volume status. JAAPA 2025;38:13\u201321. https:\/\/doi.org\/10.1097\/01.JAA.0000000000000236.","journal-title":"JAAPA"},{"key":"10169_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15559","volume":"13","author":"K Kajal","year":"2021","unstructured":"Kajal K, Premkumar M, Chaluvashetty SB, Bhujade H, Kulkarni AV. Point-of-Care thoracic ultrasonography in patients with cirrhosis and liver failure. Cureus 2021;13:e15559. https:\/\/doi.org\/10.7759\/cureus.15559.","journal-title":"Cureus"},{"key":"10169_CR29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/thoraxjnl-2017-211280","volume":"73","author":"MA Warren","year":"2018","unstructured":"Warren MA, Zhao ZG, Koyama G et al. Severity scoring of lung edema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 2018;73:840\u2013846. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211280.","journal-title":"Thorax"},{"key":"10169_CR30","doi-asserted-by":"publisher","unstructured":"Premkumar M, Kajal K, Roy A, Izzy M, Divyaveer S, Kulkarni AV, Artru F, et al. (2025) Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis. Hepatology 2026; 83: 1495-1514. https:\/\/doi.org\/10.1097\/HEP.0000000000001524.","DOI":"10.1097\/HEP.0000000000001524"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10169-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:52Z","timestamp":1789625152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10169"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10169-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Florence Wong was a consultant for Mallinckrodt Pharmaceutical Inc. during the course of the study. The consultancy contract was completed in December 2024. Dr. Ong has no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Board of Toronto General Hospital, University Health network, Toronto. Both authors had access to the study data and reviewed and approved the final manuscript.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study and patient consent is waived.","order":3,"name":"Ethics","label":"Consent participant","group":{"name":"EthicsHeading","label":"Declarations"}}]}}